Fibrosis is the abnormal deposition of extracellular matrix, which can lead to organ
dysfunction, morbidity, and death. The disease burden caused by fibrosis is substantial, and …

Structural changes involving tissue remodelling and fibrosis are major features of many
pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and …

Idiopathic pulmonary fibrosis (IPF) is a progressive and terminal lung disease with no known
cure. IPF is a disease of aging, with median age of diagnosis over 65 years. Median survival …

Cardiac fibrosis is central to the pathology of heart failure, particularly heart failure with
preserved ejection fraction (HF p EF). Irrespective of the underlying profibrotic condition (eg …

The lung's unique extracellular matrix (ECM), while providing structural support for cells, is
critical in the regulation of developmental organogenesis, homeostasis and injury-repair …

Myofibroblasts are characterized by their expression of α-smooth muscle actin, their
enhanced contractility when compared to normal fibroblasts and their increased synthetic …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrotic interstitial lung
disease, is thought to be a consequence of repetitive micro-injuries to an ageing …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of extracellular
matrix, in particular, collagens. Two IPF therapeutics, nintedanib and pirfenidone, decelerate …